HealthCor Management L.P. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 132,870 shares of the biopharmaceutical company’s stock, valued at approximately $10,259,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. Bank of New York Mellon Corp lifted its position in shares of Gilead Sciences by 199,789.8% in the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after purchasing an additional 31,335,030 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Gilead Sciences by 22.5% in the third quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock worth $5,393,502,000 after purchasing an additional 12,818,301 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in shares of Gilead Sciences by 285.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 3,998,024 shares of the biopharmaceutical company’s stock worth $308,688,000 after purchasing an additional 2,959,697 shares in the last quarter. Swedbank lifted its position in shares of Gilead Sciences by 103.7% in the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock worth $301,596,000 after purchasing an additional 1,988,987 shares in the last quarter. Finally, Natixis lifted its position in shares of Gilead Sciences by 4,550.6% in the second quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock worth $135,555,000 after purchasing an additional 1,872,389 shares in the last quarter. 78.11% of the stock is owned by institutional investors and hedge funds.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the transaction, the director now owns 3,067,762 shares in the company, valued at $239,408,146.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 150,000 shares of company stock worth $10,939,500. Corporate insiders own 1.16% of the company’s stock.

Shares of GILD opened at $65.57 on Friday. The company has a market cap of $84.82 billion, a P/E ratio of 10.21, a price-to-earnings-growth ratio of -2.54 and a beta of 1.01. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.37 and a current ratio of 3.45. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same quarter last year, the firm earned $2.27 earnings per share. Analysts predict that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be issued a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 annualized dividend and a yield of 3.48%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

A number of analysts have recently issued reports on GILD shares. Cantor Fitzgerald increased their price target on shares of Gilead Sciences from $87.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, October 26th. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, November 8th. Zacks Investment Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 25th. Raymond James reduced their price target on shares of Gilead Sciences from $97.00 to $94.00 and set a “strong-buy” rating for the company in a research report on Friday, October 26th. Finally, Barclays increased their price target on shares of Gilead Sciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, October 26th. Eleven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $88.63.

TRADEMARK VIOLATION WARNING: “HealthCor Management L.P. Takes $10.26 Million Position in Gilead Sciences, Inc. (GILD)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/healthcor-management-l-p-takes-10-26-million-position-in-gilead-sciences-inc-gild/2689564.html.

About Gilead Sciences

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Determine Your Level of Risk Tolerance

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.